Filing Overview
This Form 8-K was filed by Sharps Technology, Inc., although the request metadata identifies Skyai, Inc. The report covers events occurring primarily from April 13 through April 19, 2022.
Business Context and Material Events
- The company priced and closed an underwritten public offering of units consisting of common stock and warrants.
- The company amended an asset/share purchase agreement relating to Safegard Medical (Hungary) Kft., extending the required closing date to no later than April 22, 2022.
- Brenda Baird Simpson and Jason Monroe were elected to the board on April 15, 2022. Simpson joined the audit committee; Monroe joined the audit, compensation, and nominating committees.
Offering and Key Financial Terms
| Item | Terms |
|---|---|
| Units sold | 3,750,000 |
| Unit contents | One common share and two warrants |
| Public offering price | $4.25 per unit |
| Gross proceeds | Approximately $16.0 million, before underwriting discounts, commissions, and other expenses |
| Base warrants | 7,500,000 warrants, exercisable at $4.25 per share for five years |
| Over-allotment exercise | 1,125,000 additional warrants purchased by the underwriter; no additional shares were identified as sold under the partial exercise |
| Underwriter compensation | 8% underwriting discount, 1% non-accountable expense allowance, reimbursement of certain expenses, and warrants for 187,500 shares |
| Underwriter warrant terms | Exercise price of $5.3125 per share, equal to 125% of the public offering price |
The filing does not provide revenue, profitability, operating cash flow, cash balance, margins, debt balances, or post-offering liquidity. Net proceeds after offering costs are not clearly stated.
Changes Versus the Prior Comparable Period
- The filing is event-focused and does not present comparative financial statements or prior-period operating results.
- Capitalization changed through the issuance of 3,750,000 common shares, warrants for at least 8,625,000 shares including the over-allotment warrants, and underwriter warrants for 187,500 shares, subject to the applicable terms.
- Lock-up agreements restrict the company from disposing of covered securities for 24 months and specified officers, directors, and stockholders for 180 days, subject to exceptions and underwriter consent.
Outlook, Risks, and Unusual Items
- The company was required to complete the Safegard Medical (Hungary) Kft. purchase no later than April 22, 2022; the filing does not state whether that closing occurred.
- Exercise of the warrants could provide additional capital but would also create future share dilution. The filing does not provide a forecast of warrant exercises.
- The offering and related costs reduce gross proceeds available to the company; the filing does not specify the final net proceeds or their intended allocation.
- The company agreed to customary representations, indemnification provisions, closing conditions, and lock-up restrictions under the underwriting agreement.
Facts Investors Should Verify
- Confirm the registrant’s identity: the filing names Sharps Technology, Inc., not Skyai, Inc.
- Verify the final net proceeds after underwriting discounts, commissions, and expenses.
- Confirm the total shares outstanding after the offering and the potential dilution from all warrants.
- Verify whether the Safegard Medical acquisition or asset purchase closed by April 22, 2022.
- Review the filed underwriting agreement, warrant documents, warrant agent agreement, and purchase agreement amendment for detailed rights and contingencies.